Skip to content

HealthBreaking

Eli Lilly reports retatrutide produced more weight loss than Ozempic in trial

By

Coverage spectrum

Covered by 3 outlets across the spectrum.

3 articles in total. The spectrum counts each outlet once and leaves opinion out. How we measure bias

Business Insider, the New York Post and Scripps News report that Eli Lilly released results from a Phase 3 head-to-head trial of its experimental drug retatrutide against Ozempic. According to the company, adults with type 2 diabetes on retatrutide lost about 44 to 47 pounds over roughly a year and a half, compared with about 21 pounds on Ozempic, and retatrutide lowered A1C more. Lilly said participants lost nearly 20% to 21% of their body weight over 80 weeks. Retatrutide is not yet approved, and Lilly plans to seek regulatory approval.

Headline and summary written by Mantle’s AI from the coverage below, under published rules. How this works

What happened

Key points

Each point shows who reports it, from Far Left to Far Right.

  1. Eli Lilly released Phase 3 head-to-head trial results comparing experimental retatrutide with Ozempic on Wednesday.

    Reported byLeft1Center1Right1See the outletsHide the outlets
    Left
    Business Insider
    Center
    Scripps News
    Right
    New York Post

  2. Lilly said patients on retatrutide lost about 44 to 47 pounds, compared with about 21 pounds on Ozempic, over roughly a year and a half.

    Reported byLeft1Center1Right1See the outletsHide the outlets
    Left
    Business Insider
    Center
    Scripps News
    Right
    New York Post

  3. Lilly said retatrutide lowered A1C more than Ozempic, 2.2% versus 1.8%.

    Reported byLeft1Center1Right1See the outletsHide the outlets
    Left
    Business Insider
    Center
    Scripps News
    Right
    New York Post

  4. Lilly said participants lost nearly 20% to 21% of their body weight over 80 weeks on retatrutide.

    One outletScripps News· Center

  5. Retatrutide is not yet approved for use, and Lilly plans to seek regulatory approval.

    Reported byLeft1Center1Right1See the outletsHide the outlets
    Left
    Business Insider
    Center
    Scripps News
    Right
    New York Post

How each side tells it

Compare views

All three outlets report that Eli Lilly’s experimental drug retatrutide caused more weight loss than Ozempic in a head-to-head trial. Left casts it as a win over Ozempic, right stresses its market buzz, and center asks whether it could be the next Ozempic.

  • the left

    1 outlet

    Business Insider, the only left-side outlet in this input, uses a playful, celebratory headline that casts retatrutide as beating Ozempic and attributes the claim to Eli Lilly.

    Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
    Business InsiderLeftAll left-leaning headlines

  • the center

    1 outlet

    Scripps News frames the story as a question about whether the drug could be the next Ozempic, credits the dramatic results to Lilly and places them within the wider GLP-1 market.

    Could this drug be the next Ozempic? Lilly reports dramatic trial results
    Scripps NewsCenterAll center headlines

  • the right

    1 outlet

    The New York Post headline states the trial comparison as proven fact, measuring the drug against Ozempic’s highest dose and stressing its market buzz.

    New weight loss drug Absolutist framing“proves”The headline presents a single company-reported trial result as settled proof.More neutral: showsDisagree with this highlight? twice as powerful as Ozempic’s highest dosage
    New York PostRightAll right-leaning headlines

The words they chose

Language to notice

Words that carry a judgement beyond the facts. Tap a highlighted word anywhere on the page to see why.

  • Left0

    No loaded words in its own voice.

  • Center0

    No loaded words in its own voice.

  • Right2

    only getting biggerproves

In the outlets’ own words

  • Sensational language

    only getting biggerMore neutral: is growing

    The phrase manufactures hype about the drug rather than describing the trial data.

    …but the buzz around Eli Lilly’s experimental obesity and diabetes drug is only getting bigger.

    Used byNew York Post (Right)

  • Absolutist framing

    provesMore neutral: shows

    The headline presents a single company-reported trial result as settled proof.

    New weight loss drug proves twice as powerful as Ozempic’s highest dosage

    Used byNew York Post (Right)

See the full language guide

See for yourself

Side by side

What each side leads with and what it leaves out. Open a side to read its headlines.

From the left

1 outlet

Leads with

  • retatrutide beats Ozempic
  • weight loss more than doubled
  • playful, celebratory tone
See the headline from the leftHide the headlines

From the center

1 outlet

Leads with

  • next Ozempic question
  • results reported by Lilly
  • millions of Americans taking GLP-1 drugs
See the headline from the centerHide the headlines
  • Scripps NewsCenter

    Could this drug be the next Ozempic? Lilly reports dramatic trial results

    With millions of Americans now taking GLP-1 medications, Eli Lilly says a new experimental drug could deliver more than double the weight loss seen with current treatments. …

    Read at Scripps News (opens in a new tab)

From the right

1 outlet

Leads with

  • twice Ozempic’s highest dose
  • market buzz and blockbuster potential
  • proven superiority
See the headline from the rightHide the headlines

The stories you read build My Mix, a private picture of which sides cover the stories you choose, kept on this device. What is My Mix?

The left is Far Left and Left together. The right is Right and Far Right together. Every outlet keeps its own five-point rating.

Who reported it when

How the coverage built up

  • Left

    First to report

    Business Insider, Oct 28, 6:45 AM EDT

  • Center

    1 day 6 hr later

    Its first report, Oct 29, 1:28 PM EDT

  • Right

    5 hr 30 min later

    Its first report, Oct 28, 12:14 PM EDT

See the order the outlets reported inHide the order
  1. Business InsiderLeftOct 28, 6:45 AM EDT
  2. New York PostRightOct 28, 12:14 PM EDT
  3. Scripps NewsCenterOct 29, 1:28 PM EDT

Times are the ones the outlets published in their own feeds, in Eastern time. Opinion is left out.

Read next

Help someone else find the truth beneath the surface

Most people see one side of a story. Share this one, so they can see how every side is telling it and decide for themselves.

Email it

Seen a mistake? Tell us what is wrong with this page